JW Jungwoa Pharmaceutical Reports Operating Profit of 82.5 Billion KRW Last Year, Down 17.8% YoY

JW Pharmaceutical announced on the 7th that its consolidated operating profit for last year was 82.5 billion KRW, a decrease of 17.8% compared to the previous year.

Sales amounted to 719.4 billion KRW, down 3.9% from the previous year. Net profit increased by 75.8% to 67.6 billion KRW.

Looking at the performance by business segment, prescription drug sales increased by 0.3% to 583.7 billion KRW. Over-the-counter drug sales decreased by 8.9% to 51.6 billion KRW.

Regarding major original prescription drugs, sales of the improved new drug for dyslipidemia combination ingredient, 'Livarozet,' increased by 18.4% to 76.2 billion KRW compared to the previous year.

Sales of the hemophilia treatment 'Hemlibra' rose 107% to 48.9 billion KRW. Sales in the infusion solution segment remained at a similar level to 2023, recording 247 billion KRW compared to 247.8 billion KRW in 2023.